|
Sunday, 08/01/2010
|
Estimation of Genetic Risk Parameters from Case Control and Family Studies Using a Marginalized Approach
Jeanine Houwing-Duistermaat, Leiden University Medical Center; Roula Tsonaka, Leiden University Medical Center; Marieke De Visser, Leiden University Medical Center; Frits Rosendaal, Leiden University Medical Center
2:25 PM
|
Goodness-of-Fit Tests for Multinomial Log-Link Regression Models
Leigh Blizzard, Menzies Research Institute; Steve John Quinn, Menzies Research Institute; David W. Hosmer, University of Massachusetts, Amherst; Jana D. Canary, University of Tasmania
2:35 PM
|
The Philosophy and Intent of Stability Shelf Life
David Christopher, Merck & Co., Inc.
3:05 PM
|
A Joint Model for Longitudinal Measurements and Competing Risks Survival Data
Gang Li, University of California, Los Angeles
3:05 PM
|
Mapping Local Risk Ratios of Rare Infectious Diseases with Aggregate Data
Nong Shang, CDC
3:20 PM
|
Benchmark Dose Analysis from Multiple Data Sets: The Cumulative Risk Assessment for N-Methyl Carbamate Pesticides
Rhyne Woodrow Setzer, U.S. Environmental Protection Agency
4:05 PM
|
Simulation of Risk of Codling Moth Establishment from Imported Apples
Eleanor Shannon Neeley, Brigham Young University
4:20 PM
|
Determination of Optimal Cut Point for Competing Risks Data
Jeong Youn Lim, University of Pittsburgh; Jong-Hyeon Jeong, University of Pittsburgh
4:35 PM
|
Optimal Designs for Toxicology Studies with Multiple Responses and Multiple Stressors
Edward L. Boone, Virginia Commonwealth University; David Edwards, Virginia Commonwealth University; Shuchi Jain, Virginia Commonwealth University
4:35 PM
|
Updated Risk Assessment of Variant Creutzfeldt-Jakob Disease (vCJD) Risks for Recipients of Blood and Plasma-Derived Products in the United States
Steven Anderson, FDA; Hong Yang, FDA; Richard Forshee, FDA; Mark Walderhaug, FDA
4:50 PM
|
A Novel Bayesian Approach to Assessing the Risk of QT Prolongation
Suraj Anand, Novartis Pharmaceuticals Corporation; Sujit Kumar Ghosh, North Carolina State University
5:05 PM
|
Statistical Disclosure Risk of Synthetic Datasets
Anne-Sophie Charest, Carnegie Mellon University
5:05 PM
|
Multiplicative Semiparametric Regression Model for Relative Risk with Application to Air Pollution Exposure
Catherine Tuglus, University of California, Berkeley; Kristin E. Porter, University of California, Berkeley; Mark J. Van der Laan, University of California, Berkeley
5:20 PM
|
Different Approaches to Model Averaging in Environmental Risk Assessment
Esben Budtz-Jørgensen, University of Copenhagen
5:20 PM
|
|
Monday, 08/02/2010
|
Prediction of Pneumococcal Nonvaccination Among Persons Aged >= 65 Years
Fan Zhang, CDC; Wei Yu, CDC; Tiebin Liu, CDC; Peng-Jun Lu, CDC; Faruque Ahmed, CDC
|
Robust Inference in Some Multiple Multifactor Dynamical Systems
Sévérien Nkurunziza, University of Windsor
|
Computing the Standard Error of the Relative Risk of Dementia versus Death in a Multistate Nonstationary Markov Chain
Lei Yu, Rush Alzheimer's Disease Center; Richard J. Kryscio, University of Kentucky
|
Using Bayesian Logistic Regression to Estimate the Risk or Prevalence Ratio
Charles E. Rose, Jr., CDC; Andrew Lewis Baughman, CDC
|
Improvements in Ability to Detect Undiagnosed Diabetes by Using Information on Family History Among Adults in the United States
Quanhe Yang, CDC; Tiebin Liu, CDC; Ramal Mooneshinghe, CDC; Rodolfo Valdez, CDC; Muin Khoury, CDC
|
Overweight Distribution and Spatial Risk for Binomial Response
Lia Zangirolani, State University of Campinas; Ricardo Carlos Cordeiro, State University of Campinas - Unicamp; Luciana Bertoldi Nucci, State University of Campinas; Ana Carolina Cintra Nunes Mafra, State University of Campinas - Unicamp; Maria Angelica Tavares Medeiros, Pontificia Universidad Católica de Campinas; Liciana Vaz Arruda Silveira, Universidade Estadual Paulista Júlio de Mesquita Filho
|
Competing Risks Methods in Safety Analysis of Oncology Clinical Trials
Sofia Paul, Novartis Pharmaceuticals Corporation; Bingqing Zhou, The University of North Carolina at Chapel Hill; Samit Hirawat, Novartis Pharma; Glen Laird, Novartis Pharmaceuticals Corporation
|
Logistic Regression with Markov Chains as Covariates with Application in Identifying Lung Cancer Risk Factors
Chung-Han Ho, The University of Texas School of Public Health; Carol J. Etzel, MD Anderson Cancer Center; Wenyaw Chan, The University of Texas School of Public Health; Randa El-Zein, MD Anderson Cancer Center; Alanna C. Morrison, The University of Texas School of Public Health
|
The Promise and Challenge of Benefit: Risk Analysis for Medical Products
Richard Forshee, FDA
|
Risk Predictions from Genomewide Association Data
Hongyu Zhao, Yale University; Jia Kang, Yale University; Ruiyan Luo, Yale University; Judy Cho, Yale University
8:35 AM
|
Risk Analysis in a Multivariate World
Xunguo Lin, CSIRO; Simon Christopher Barry, CSIRO; Vijay Satyal, Oregon Department of Energy
8:35 AM
|
Contact Histories from the Survey of Grouped Individuals: Multivariate Multilevel Survival Analysis of Grouped Censored Data with Competing Risks
Hiroaki Minato, NORC
9:50 AM
|
Comparison of Cure Rate Models in Competing Risks Framework
Sanjib Basu, Northern Illinois University; Suchitrita Sarkar, Northern Illinois University
10:35 AM
|
Using Disease Surveillance Data to Forecast Disease Risk
Al Ozonoff, Boston University School of Public Health; Yorghos Tripodis, Boston University; John Brownstein, Children's Hospital Boston
10:35 AM
|
Modeling Bond-Trading Behavior Using a Zero-Inflated Multivariate Poisson
Bonnie Kathryn Ray, IBM T.J. Watson Research Center; Sarah Thomas, Rice University; Katherine Bennett Ensor, Rice University
10:35 AM
|
Procedures to Reduce the Risk of Disclosure in Health Surveys
Meena Khare, National Center for Health Statistics; Joe Fred Gonzalez, Jr., National Center for Health Statistics; Peter Meyer, National Center for Health Statistics
10:55 AM
|
Comparing the Cumulative False-Positive Risk of Screening Mammography Programs Using a Discrete Time Survival Model Allowing for Nonignorable Drop-Out
Rebecca Hubbard, Group Health Research Institute; Diana Miglioretti, Group Health Research Institute
11:05 AM
|
The Influence of Prior Experiences in Managing Current and Future Risks During Survey Transition Points on the National Survey on Drug Use and Health (NSDUH)
Joe Gfroerer, Substance Abuse and Mental Health Services Administration; Jonaki Bose, Substance Abuse and Mental Health Services Administration
11:25 AM
|
Feature Selection for Censored Outcomes with Simultaneous Adjustment for Nonlinear Covariate Effect and Improved Risk Scores of Prostate Cancer Recurrence
Qi Long, Emory University; Brent Johnson, Emory University; Carlos S. Moreno, Emory University
11:35 AM
|
Reliability Models for Single Repairable Systems and Some Nonstandard Inference
Ananda Sen, University of Michigan
11:35 AM
|
Joint Matching on Propensity Scores and Disease Risk Scores in Observational Studies of Drug Effects
Robert Glynn, Brigham and Women's Hospital
11:35 AM
|
Survival Analysis with Error-Prone Time-Varying Covariates: A Risk Set Calibration Approach
Xiaomei Liao, Harvard University; David M. Zucker, Hebrew University; Yi Li, Harvard University/Dana-Farber Cancer Institute; Donna Spiegelman, Harvard University
11:50 AM
|
Cox Regression Model with Time-Varying Coefficients in Nested Case-Control Studies
Mengling Liu, New York University School of Medicine; Wenbin Lu, North Carolina State University; Anne Zeleniuch-Jacquotte, New York University School of Medicine; Roy E. Shore, Radiation Effects Research Foundation
2:05 PM
|
A Joint Longitudinal and Illness-Death Model
Elizabeth Renata Brown, University of Washington
2:25 PM
|
Hypothesis Testing of Treatment Policies in Two-Stage Randomization Designs
Xiang Guo, sanofi-aventis (China); Anastasios Tsiatis, North Carolina State University
2:30 PM
|
Prediction via Sparse Kernel PCA
Tianxi Cai, Harvard School of Public Health
2:35 PM
|
Bayesian Joint Model of Multivariate Ordinal Data with Competing Risks Survival Time
Pulak Ghosh, Indian Institute of Management, Bangalore
3:05 PM
|
Design and Analysis of Bioassay Experiments, Risk Issues
Michael E. Tarter, University of California, Berkeley
3:25 PM
|
|
Tuesday, 08/03/2010
|
Depression, Fracture Risk, and Bone Loss: A Meta-Analysis of Cohort Studies
Qing Wu, Mayo Clinic; Jianing Liu, Arizona State University; Juan F. Gallegos-Orozco, Mayo Clinic; Joseph G. Hentz, Mayo Clinic
|
High Dimentional ROC Analysis Can Improve the Correlation Between Histological Grade (HG) and Oncotype-Dx (ONC) Recurrence Risk (RR) in Breast Cancer (BC)
Yufeng Li, The University of Alabama at Birmingham; Choo Hyung Lee, The University of Alabama at Birmingham; Omar Hameed, The University of Alabama at Birmingham
|
Risky Business: The 'Failures' of Risk Management
Christine Wu, North Carolina State University; John Ryland Pigg, North Carolina State University
|
Are Official Statistics at Risk of Losing Their Preeminent Status with Governments and Society?
Brian Pink, Australian Bureau of Statistics
|
A Comparison of Change Point Methods for Lymph Node Risk Factors in Three Cancers
Marianne Huebner, Mayo Clinic; Rui Qin, Mayo Clinic
|
Identifying and Reducing Risk Factors for CDISC-Compliant Submissions: How It Affects Programmers
Rachna Mittal, Genentech; Todd Case, Bristol-Myers Squibb
|
Using Statistical Concepts to Determine Risk Level of Randomized Clinical Trials That Compare Two Noninvestigational Therapies
Martin L. Lesser, Feinstein Institute for Medical Research; Nina E. Kohn, Feinstein Institute for Medical Research
|
Some Issues in Risk Analysis of Drug Products
Tony Lachenbruch, Oregon State University
|
Discovering Influential Variables: A Partition-Based Learning Method to Identify Susceptible Genetic Risk Factors in Common Human Disorders
Tian Zheng, Columbia University; Herman Chernoff, Harvard University; Shaw-Hwa Lo, Columbia University
8:35 AM
|
Estimating Reduction in Absolute Breast Cancer Risk in Individuals and Populations from Modifying Risk Factors
Elisabetta Petracci, Institute of Medical Statistics and Biometry ; Adriano Decarli, Institute of Medical Statistics and Biometry ; Domenico Palli, Scientific Institute of Tuscany; Giovanna Masala, Scientific Institute of Tuscany; David Pee, Information Management Service Inc.; Ruth Pfeiffer, National Cancer Institute; Catherine Schairer, Division of Cancer Epidemiology and Genetics; Mitchell H. Gail, National Cancer Institute
8:50 AM
|
Estimating Functionals of Multistate Processes Under Cross-Sectional Sampling
Micha Mandel, Hebrew University of Jerusalem
8:55 AM
|
Outliers in GARCH Models and the Estimation of Risk Measures
Helena Veiga, Universidad Carlos III de Madrid; Aurea Grané, Universidad Carlos III de Madrid
9:20 AM
|
The NPMLE of the Joint Distribution Function with Right-Censored and Masked Competing Risks Data
Qiqing Yu, Binghamton University
9:35 AM
|
A Frailty-Model-Based Approach to Estimating the Age-Dependent Penetrance Function of a Gene Mutation Using Family-Based Study Designs
Yun-Hee Choi, The University of Western Ontario; Laurent Briollais, Samuel Lunenfeld Research Institute
9:35 AM
|
Estimation of Mercury in Fish
Pepi Lacayo, U.S. Environmental Protection Agency
9:35 AM
|
Modeling the Dynamics of Corporate Credit Ratings: Creating a Predictive Ratings Model
Meghan Rachel Kent, North Carolina State University; Terri Anna Johnson, North Carolina State University; Nicole Bader, North Carolina State University; Jenna Rice, North Carolina State University
10:05 AM
|
The Interplay Between Body Mass Index, Prostate-Specific Antigen, and Prostate Cancer Risk
Yuanyuan Liang, The University of Texas Health Science Center at San Antonio; Donna Pauler Ankerst, Technical University; Michael Sanchez, The University of Texas at San Antonio; Robin J. Leach, The University of Texas Health Science Center at San Antonio; Ian Murchie Thompson, The University of Texas Health Science Center at San Antonio
10:35 AM
|
Evaluating Cardiovascular Risk in Diabetes Clinical Trials: Lessons Learned from Saxagliptin
J Mark Donovan, Bristol-Myers Squibb
10:35 AM
|
Overdiagnosis and the Will Rogers Effect: Bias in Risk Adjustment
Daniel Gottlieb, The Dartmouth Institute for Health Policy and Clinical Practice; Jason Sutherland, Centre for Health Services and Policy Research
10:35 AM
|
Multiplicity Issues in Meta-Analyses to Rule Out an Unacceptable Cardiovascular Risk
Stefan Hantel, Boehringer Ingelheim Pharmaceuticals, Inc.
10:55 AM
|
Evaluating Cardiovascular Risk in Diabetes Clinical Trials: An FDA Statistician's Perspective
Jon Todd Sahlroot, FDA
11:15 AM
|
Prospective Safety Analysis Plans: Critical Elements and Principles
George Rochester, FDA
11:35 AM
|
Challenges in Predicting Risk of Women Diseases Using Genomic Data
Mariza De Andrade, Mayo Clinic
11:55 AM
|
Nonparametric Test of Conditional Quantile Independence with an Application to Banks' Systemic Risk
Milan Nedeljkovic, University of Warwick
12:05 PM
|
Noninferiority Trial Designs for Odds Ratios and Risk Differences
Joan Hilton, University of California, San Francisco
2:05 PM
|
Multivariate Dyadic Regression Trees for Sparse Learning Problems
Han Liu, Carnegie Mellon University; Xi Chen, Carnegie Mellon University
2:05 PM
|
Sample-Size Calculation for the Andersen-Gill Model in the Presence of Subject Heterogeneity in the Baseline Risk
Antje Jahn-Eimermacher, University of Mainz; Katharina Ingel, University of Mainz
2:20 PM
|
Transition from Genetic Studies to Personalized Medicine: A Consulting Experience
Fang-Chi Hsu, Wake Forest University School of Medicine
2:25 PM
|
Benchmark Dose Estimation in Environmental Risk Assessment: From Cancer to Genetic Toxicity and Beyond
Walter W. Piegorsch, The University of Arizona
3:20 PM
|
|
Wednesday, 08/04/2010
|
Evaluation and Management of Cost Structures in Statistical Work with Administrative Record Data
John L. Eltinge, Bureau of Labor Statistics
|
Calculation of Sample Size for Testing the Performance of Disease Risk Prediction Models from Survival Analysis Based on Harrell's C Discrimination Index
Ching-Yu Huang, National Health Research Institutes, Taiwan; Hsing-Yi Chang, National Health Research Institutes, Taiwan; Wen-ling Liu, National Health Research Institutes, Taiwan
|
Statistical Risk Assessment for Chemical Substances
Koji Kanefuji, The Institute of Statistical Mathematics; Takayuki Fujii, The Institute of Statistical Mathematics; Masayuki Kageyama, The Institute of Statistical Mathematics ; Masashi Gamo, National Institute of Advanced Industrial Science and Technology; Hiroe Tsubaki, The Institute of Statistical Mathematics
|
Risk Stratification Using Survival and Microarray Gene Expression Data
Pingping Qu, Cancer Research and Biostatistics (CRAB); John D. Shaughnessy Jr., University of Arkansas for Medical Sciences; Michael LeBlanc, Fred Hutchinson Cancer Research Center; Jeff Haessler, Cancer Research and Biostatistics (CRAB); Bart Barlogie, University of Arkansas for Medical Sciences; John Crowley, Cancer Research and Biostatistics (CRAB)
|
Statistical Analysis of Bipartite and Multipartite Ranking by Convex Risk Minimization
Kazuki Uematsu, The Ohio State University; Yoonkyung Lee, The Ohio State University
|
Bayesian Goodness-of-Fit Test and Semiparametric Generalization with Measurement Data
Angela Schoergendorfer, University of Kentucky; Adam J. Branscum, University of Kentucky; Timothy Edward Hanson, University of Minnesota
|
Bayesian and Frequentist Methods for Provider Profiling Using Risk-Adjusted Assessments of Medical Outcomes
Michael Joseph Racz, Albany College of Pharmacy and Health Sciences; Joseph Sedransk, Case Western Reserve University
8:35 AM
|
Visualizing Risks, Benefits, and Uncertainty in Three Dimensions
Richard Forshee, FDA; Mark Walderhaug, FDA; Arianna Simonetti, FDA; Anne Fernando, Norfolk State University
8:50 AM
|
Assessing the Goodness of Fit of Risk Prediction Rules in a Clustered Data Setting
Bernard Rosner, Harvard Medical School; Weiliang Qiu, Harvard Medical School; MeiLing Ting Lee, University of Maryland
8:55 AM
|
Application of Methods for Assessing Risk-Benefit in Clinical Trials
Menghui Chen, Merck & Co., Inc.; Shailaja Suryawanshi, Merck & Co., Inc.
9:05 AM
|
Cause-Specific Association Measures for Multivariate Competing Risks Data
Yu Cheng, University of Pittsburgh; Hao Wang, University of Pittsburgh
9:15 AM
|
Assessing Treatment Effect in Clinical Trials with Dichotomous Endpoints
Gang Jia, Merck & Co., Inc.
9:20 AM
|
The Bayesian Hierarchical Model for Estimating the Size of HIV At-Risk Populations in Bangladesh
Le Bao, University of Washington; Adrian E. Raftery, University of Washington; Amala Reddy, UNAIDS Regional Support Team Asia-Pacific
9:20 AM
|
PartDSA: The Partitioning Deletion/Substitution/Addition Algorithm for Creating Survival Risk Groups
Karen Lostritto, Yale University; Rob Strawderman, Cornell University; Annette Molinaro, Yale University
9:20 AM
|
The Reliability of Signal Analysis in the Adverse Events Setting of Priorities
Qian Graves, FDA/CFSAN; Peng T. Liu, FDA; Stuart Chirtel, FDA/CFSAN; Curtis Barton, FDA/CFSAN; Debra Street, FDA/CFSAN
9:20 AM
|
The Value of Personalized, Predictive Risk-Assessment Tools for the Prevention of Chronic Diseases
Edward J. Moler, Tethys Bioscience, Inc.; Louis P. Garrison, University of Washington; Janice Kolberg, Tethys Bioscience, Inc.; Harald Rinde, BioBridge Strategies Switzerland; Sean D. Sullivan, University of Washington
9:35 AM
|
Cluster Detection Using Scan Statistics and Risk Factors for Encephalitis from West Nile Virus Infection
Sarah Baraniuk, The University of Texas Health Science Center at Houston; Kristy Murray, The University of Texas Health Science Center at Houston
9:35 AM
|
Interval Estimation of Epidemiological Indices for Data Sampled from Clusters: A Review and an Extension
Tasneem Zaihra, University of New Brunswick; Sudhir Paul, University of Windsor
9:50 AM
|
Automobile Warranty Data Analysis
Jaiwook Baik, Korea National Open University
9:50 AM
|
Benefit Risk Assessment Incorporating Time Component
Paulette Ceesay, Merck & Co., Inc.; Richard Entsuah, Merck & Co., Inc.
9:50 AM
|
Intensity-Based Estimation of Extreme Loss Event Probability and Value-at-Risk
Kam Hamidieh, Rice University; Stilian Stoev, University of Michigan; George Michailidis, University of Michigan
10:35 AM
|
Almost Unbiased Maximum Likelihood Estimation for the Generalized Pareto Distribtion and Value at Risk
David E. Giles, University of Victoria; Hui Feng, King's College/The University of Western Ontario
10:50 AM
|
Baysian Semiparametric Regression Under Competing Risks
Xiaolin Fan, Novartis Pharmaceuticals Corporation; Purushottam W. Laud, Medical College of Wisconsin
10:55 AM
|
Cancer Risk in the Environment: Public Policy Issues in Screening
Karen Kafadar, Indiana University; Philip Prorok, National Cancer Institute
11:05 AM
|
A Bayesian Hierarchical Spatial Approach for Constructing Disease Risk Maps at a Finer Level Than Is Provided in Publicly Available Data
Fu-Chi Hsieh, Yale University; Theodore R. Holford, Yale University
11:05 AM
|
A Dose-Finding Method in Joint Modeling of Efficacy and Safety: An Extension of the MCP-Mod Method
Aiyang Tao, Novartis; Yong Lin, University of Medicine and Dentistry of New Jersey; Jose Carlos Pinheiro, Johnson & Johnson; Weichung J. Shih, University of Medicine and Dentistry of New Jersey
11:35 AM
|
Multiregional Trials Using Bayesian Statistical Approach
Kyoungah See, Eli Lilly and Company; Robert Noble, GSK
11:35 AM
|
Quarantine Inspection: How Risky a Business?
Andrew Robinson, ACERA/University of Melbourne; Mark Burgman, ACERA/University of Melbourne; Rob Cannon, DAFF
2:05 PM
|
Decomposition of Kullback-Leibler Risk with Applications to Exponential Families
Qiang Wu, East Carolina University; Paul Vos, East Carolina University
2:20 PM
|
Bagged Estimators for Joint Longitudinal and Survival Analysis
Harsh Singhal, Bank of America
2:20 PM
|
Evaluation and Interpretation of Diagnostic Tests
Bipasa Biswas, FDA/CDRH
2:45 PM
|
Nonparametric Estimation of Concordance Probability with Censored Data
Mithat Gonen, Memorial Sloan-Kettering Cancer Center; Glenn Heller, Memorial Sloan-Kettering Cancer Center; Qianxing Mo, Memorial Sloan-Kettering Cancer Center
2:45 PM
|
Bayesian Nonparametric Estimation of Regression Models in Event History Analysis
Pierpaolo De Blasi, University of Turin/Collegio Carlo Alberto
3:05 PM
|
|
Thursday, 08/05/2010
|
Risk Models for Deciding Whether to Take Tamoxifen to Prevent Breast Cancer and for Allocating Public Health Resources
Mitchell H. Gail, National Cancer Institute
8:35 AM
|
Some Risks with Bayes and Some Higher-Order Truths
Donald A.S. Fraser, University of Toronto
8:35 AM
|
On the Ability of Breast Cancer-Associated SNPs to Augment Clinical Variables in Predicting Breast Cancer Risk
Ross L. Prentice, Fred Hutchinson Cancer Research Center; David A. Hinds, Perlegen Sciences
8:35 AM
|
Coherent Analysis of Longitudinal Changes in Biomarkers in the Presence of Attrition Due to Competing Risks
Tom Greene, The University of Utah
8:35 AM
|
Biomarkers in Clinical Trials in the Development of Biologics and Risk Assessment
Samir Lababidi, FDA
8:50 AM
|
Risk Stratification Markers in Clinical Practice: An FDA Perspective
Estelle Russek-Cohen, FDA
9:00 AM
|
Study Designs for Evaluating Personal Risk Models
Alice S. Whittemore, Stanford University
9:05 AM
|
Using Cardiovascular Disease Risk Functions in Public Health and Clinical Trial: The Framingham Study Experience
Ralph B. D'Agostino, Sr., Boston University
9:25 AM
|
A Stochastic Search Approach to Solving the Cell Suppression Problem for Three-Dimensional Hierarchical Tables
Matt Fetter, National Agricultural Statistics Service
11:05 AM
|
Multistate Modeling Approaches for Estimating Disease Risk in Gene Mutation Carriers from Family Data
Karen Kopciuk, Alberta Health Services; Yun-Hee Choi, The University of Western Ontario; Laurent Briollais, Samuel Lunenfeld Research Institute; Patrick Parfrey, Memorial University; Jane Green, Memorial University
11:25 AM
|
Field-Failure and Warranty Prediction Based on Auxiliary Use-Rate Information
Yili Hong, Virginia Tech; William Q. Meeker, Iowa State University
11:35 AM
|
|